Risk adjusted net present value: What is the current valuation of Kymera Therapeutics’s KT-413?

KT-413 is a small molecule commercialized by Kymera Therapeutics, with a leading Phase I program in Primary CNS Lymphoma.

Wearable tech reveals: Social constructs and physical activity shape global sleep patterns

Researchers analyze sleep data from wearable devices to assess sleep patterns. Societal factors influence sleep quality and quantity, with exercise playing a positive role. Understanding

June 20, 2023

Immunic to Participate in Scientific Conferences in October – Biotech Investments

Issuer: Immunic, Inc. / Key word(s): Conference 04.10.2023 / 12:30 CET/CEST The issuer is solely responsible for the content of this announcement. Immunic to Participate

October 5, 2023

Microbial decoration enhances drug delivery specificity and safety

Announcing a new publication for Acta Materia Medica journal. Microorganisms are mostly distributed on the surface of our skin and intestines and have crucial roles

December 30, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.